TY - JOUR
T1 - Clinical and patient-reported trajectories at end-of-life in older patients with advanced CKD
AU - Chesnaye, Nicholas C.
AU - Caskey, Fergus J.
AU - Dekker, Friedo W.
AU - de Rooij, Esther N. M.
AU - the EQUAL study investigators
AU - Maria Pippias, Marie Evans
AU - Torino, Claudia
AU - Porto, Gaetana
AU - Szymczak, Maciej
AU - Drechsler, Christiane
AU - Wanner, Christoph
AU - Heimburger, Olof
AU - Jager, Kitty J.
AU - Vogt, L.
N1 - Funding Information: Main funding was received from the European Renal Association (ERA) and contributions from the Swedish Medical Association (SLS), the Stockholm County Council ALF Medicine and Center for Innovative research (CIMED), the Italian Society of Nephrology (SIN-Reni), the Dutch Kidney Foundation (SB 142), the Young Investigators grant in Germany, and the National Institute for Health Research in the United Kingdom. Funding Information: M.E. reports no conflict of interest in relation to this publication. Outside this work, M.E. reports payment for advisory boards and lectures by Astellas pharma, Vifor Pharma, and Astra Zeneca, and institutional grants from Astra Zeneca and Astellas pharma. C.W. had no conflict in respect to the present research. Outside this research, honoraria for consultancy and lecturing were received from Amicus, AstraZeneca, Bayer, Boehringer-Ingelheim, Eli-Lilly, GILEAD, GSK, MSD, Sanofi-Genzyme, and Takeda. Publisher Copyright: © 2023 Oxford University Press. All rights reserved.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background. We explore longitudinal trajectories of clinical indicators, patient-reported outcomes, and hospitalizations, in the years preceding death in a population of older patients with advanced chronic kidney disease (CKD). Methods. The EQUAL study is a European observational prospective cohort study with an incident eGFR <20 ml/min per 1.73 m2 and ≥65 years of age. The evolution of each clinical indicator was explored using generalized additive models during the 4 years preceding death. Results. We included 661 decedents with a median time to death of 2.0 years (IQR 0.9–3.2). During the years preceding death, eGFR, Subjective Global Assessment score, and blood pressure declined, with accelerations seen at 6 months preceding death. Serum hemoglobin, hematocrit, cholesterol, calcium, albumin, and sodium values declined slowly during follow-up, with accelerations observed between 6 and 12 months preceding death. Physical and mental quality of life declined linearly throughout follow-up. The number of reported symptoms was stable up to 2 years prior to death, with an acceleration observed at 1 year prior to death. The rate of hospitalization was stable at around one hospitalization per person year, increasing exponentially at 6 months preceding death. Conclusions. We identified clinically relevant physiological accelerations in patient trajectories that began ∼6 to 12 months prior to death, which are likely multifactorial in nature, but correlate with a surge in hospitalizations. Further research should focus on how to effectively use this knowledge to inform patient and family expectations, to benefit the planning of (end-of-life) care, and to establish clinical alert systems.
AB - Background. We explore longitudinal trajectories of clinical indicators, patient-reported outcomes, and hospitalizations, in the years preceding death in a population of older patients with advanced chronic kidney disease (CKD). Methods. The EQUAL study is a European observational prospective cohort study with an incident eGFR <20 ml/min per 1.73 m2 and ≥65 years of age. The evolution of each clinical indicator was explored using generalized additive models during the 4 years preceding death. Results. We included 661 decedents with a median time to death of 2.0 years (IQR 0.9–3.2). During the years preceding death, eGFR, Subjective Global Assessment score, and blood pressure declined, with accelerations seen at 6 months preceding death. Serum hemoglobin, hematocrit, cholesterol, calcium, albumin, and sodium values declined slowly during follow-up, with accelerations observed between 6 and 12 months preceding death. Physical and mental quality of life declined linearly throughout follow-up. The number of reported symptoms was stable up to 2 years prior to death, with an acceleration observed at 1 year prior to death. The rate of hospitalization was stable at around one hospitalization per person year, increasing exponentially at 6 months preceding death. Conclusions. We identified clinically relevant physiological accelerations in patient trajectories that began ∼6 to 12 months prior to death, which are likely multifactorial in nature, but correlate with a surge in hospitalizations. Further research should focus on how to effectively use this knowledge to inform patient and family expectations, to benefit the planning of (end-of-life) care, and to establish clinical alert systems.
KW - chronic kidney disease
KW - end-of-life
KW - mortality
UR - http://www.scopus.com/inward/record.url?scp=85177162170&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/ndt/gfad091
DO - https://doi.org/10.1093/ndt/gfad091
M3 - Article
C2 - 37193666
SN - 0931-0509
VL - 38
SP - 2494
EP - 2502
JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
IS - 11
ER -